Impact of Early Antiretroviral Treatment Initiation on Performance of Cross-Sectional Incidence Assays.
Adolescent
Adult
Anti-Retroviral Agents
/ therapeutic use
Antibody Affinity
Cohort Studies
Cross-Sectional Studies
/ standards
Female
HIV Antibodies
/ blood
HIV Infections
/ drug therapy
HIV-1
/ drug effects
Humans
Incidence
Male
Mass Screening
/ standards
Sustained Virologic Response
Time Factors
Transgender Persons
Viral Load
Young Adult
HIV incidence
antibody avidity
antiretroviral therapy
limiting antigen avidity
Journal
AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
pubmed:
17
4
2020
medline:
2
7
2021
entrez:
17
4
2020
Statut:
ppublish
Résumé
Antiretroviral therapy (ART) can impact assays used for cross-sectional HIV incidence testing, causing inaccurate HIV incidence estimates. We evaluated the relationship between the timing of ART initiation and the performance of two serologic HIV incidence assays. We analyzed 302 samples from 55 individuals from the RV217 cohort (Early Capture HIV Cohort Study). Participants were grouped by ART start time: ART started <1 year after infection (
Identifiants
pubmed: 32295382
doi: 10.1089/AID.2019.0286
pmc: PMC7398433
doi:
Substances chimiques
Anti-Retroviral Agents
0
HIV Antibodies
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
583-589Subventions
Organisme : NIAID NIH HHS
ID : R01 AI095068
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068613
Pays : United States
Références
N Engl J Med. 2016 Jun 2;374(22):2120-30
pubmed: 27192360
N Engl J Med. 2018 May 17;378(20):1859-1861
pubmed: 29768142
PLoS One. 2010 Oct 11;5(10):e13259
pubmed: 20949006
AIDS Res Hum Retroviruses. 2018 Oct;34(10):863-866
pubmed: 29926735
Clin Infect Dis. 2006 Mar 1;42(5):700-8
pubmed: 16447118
Clin Infect Dis. 2016 Aug 15;63(4):555-61
pubmed: 27317797
Stat Commun Infect Dis. 2017 Mar;9(1):
pubmed: 29527254
EBioMedicine. 2016 Sep;11:68-72
pubmed: 27460436
J HIV AIDS Surveill Epidemiol. 2010 Jan 1;2(1):1-14
pubmed: 21743821
AIDS. 2016 Sep 24;30(15):2361-71
pubmed: 27454561
AIDS Res Hum Retroviruses. 2014 Apr;30(4):339-44
pubmed: 24083837
AIDS Res Hum Retroviruses. 2015 Apr;31(4):421-7
pubmed: 25317854
PLoS One. 2013 Dec 27;8(12):e82772
pubmed: 24386116
BMC Infect Dis. 2017 Sep 29;17(1):653
pubmed: 28969607
AIDS Res Hum Retroviruses. 2017 Sep;33(9):902-904
pubmed: 28443672
Viruses. 2019 Jul 03;11(7):
pubmed: 31277299
J Int AIDS Soc. 2018 Feb;21(2):
pubmed: 29489059
JAMA. 1998 Jul 1;280(1):42-8
pubmed: 9660362
J Acquir Immune Defic Syndr. 2010 Aug;54(4):406-14
pubmed: 20436353
PLoS One. 2013;8(2):e55525
pubmed: 23437058
Euro Surveill. 2008 Sep 04;13(36):
pubmed: 18775293
AIDS Res Hum Retroviruses. 2012 Oct;28(10):1177-83
pubmed: 22283149
AIDS. 2014 May 15;28(8):1227-32
pubmed: 24513567
Lancet Glob Health. 2014 May;2(5):e267-77
pubmed: 25103167